Global Chiral Chromatography Reagents Market Outlook, 2031

Chirality is one of the most consequential properties in drug development: more than half of marketed small molecule drugs contain at least one stereocentre, and two mirror-image enantiomers of the same molecule can differ sharply in potency, metabolism and toxicity. Chiral chromatography reagents make it possible to separate, measure and purify these enantiomers. The category includes chiral stationary phases, led by polysaccharide-based amylose and cellulose derivatives that resolve an estimated 80% to 90% of chiral compounds screened in pharmaceutical laboratories, as well as Pirkle-type brush phases, macrocyclic glycopeptides, cyclodextrins, crown ethers, protein-based phases and ligand exchange phases. It also covers chiral derivatising agents such as Marfey's reagent and Mosher's acid, chiral mobile phase additives, and the solvents and modifiers used in normal-phase, reversed-phase, polar organic and supercritical fluid chromatography. The supplier landscape is concentrated, with Daicel's Chiral Technologies the long-standing leader through its CHIRALPAK and CHIRALCEL lines, followed by Phenomenex within Danaher, Regis Technologies, Agilent, Waters, Merck KGaA, Thermo Fisher, YMC, Shimadzu, Sumika and a growing number of Chinese producers.

Regulation is the bedrock of demand. Since the US FDA's 1992 policy on stereoisomeric drugs, developers have been expected to characterise each enantiomer, and ICH guidelines require enantiomeric purity to be specified and controlled, typically with impurity limits around 0.1% to 0.15% for the unwanted enantiomer. Chiral switches, in which single-enantiomer versions replace racemic drugs, and the steady flow of chiral new chemical entities keep analytical and preparative demand high. Supercritical fluid chromatography has transformed preparative chiral separations, cutting organic solvent use by 70% to 90% compared with normal-phase HPLC and speeding solvent removal, so large pharmaceutical companies and CDMOs now run SFC as their default technique for purifying kilogram quantities of enantiomers. Immobilized polysaccharide phases, which tolerate a much wider range of solvents than coated phases, have expanded method options. Growth areas include chiral agrochemicals, flavours and fragrances, and the analysis of chiral impurities in peptides and oligonucleotides. Competition from asymmetric synthesis and biocatalysis, which produce single enantiomers directly, limits preparative growth, but analytical verification remains mandatory. Industry consolidation, including Waters' 2025 agreement to combine with BD's biosciences business, is reshaping the broader chromatography supply base.

Drivers Regulatory Requirements for Enantiomeric Purity Regulators require developers to characterised and control enantiomers of chiral drugs, and pharmacopoeial methods specify chiral separations for many products, ensuring continuous demand for chiral columns and reagents in development and quality control. Chiral impurity testing is also required for generic drugs.
Pharmaceutical Pipelines and Preparative SFC A large share of new small molecule drugs are chiral, and pharmaceutical companies and CDMOs use preparative chiral HPLC and SFC to supply enantiomerically pure material for toxicology and clinical studies. SFC's speed and lower solvent use have increased throughput and adoption.

Challenges High Column Costs and Method Development Complexity Chiral columns are expensive and method development is often empirical, requiring screening of multiple phases and solvents. Selection depends on expert knowledge, and a single dominant supplier for key phases creates pricing power and supply concentration.
Competition from Asymmetric Synthesis and Biocatalysis Advances in asymmetric catalysis, biocatalysis and crystallisation-based resolution allow manufacturers to produce single enantiomers without preparative chromatography at commercial scale, limiting large-scale preparative demand to early development and specific cases.

Trends Immobilized Polysaccharide Phases and Sub-2-Micron Columns Immobilized amylose and cellulose phases compatible with a wide range of solvents are replacing coated phases in many methods, while smaller particles and core-shell chiral columns enable faster, higher-resolution UHPLC and SFC separations.
Automated Screening and Green Chiral Separations Automated screening systems test multiple columns and mobile phases overnight, accelerating method development, and AI-assisted column selection tools are emerging. SFC and greener solvents reduce environmental impact and cost in both analytical and preparative work.



Chiral stationary phases account for the largest share of chiral chromatography reagent spending because the column chemistry performs the enantiomer separation, and polysaccharide-based phases resolve most pharmaceutical compounds, making them the central purchase in every chiral laboratory. Chiral stationary phases are the core of the market. Polysaccharide-based phases, made from amylose and cellulose derivatives such as tris(3,5-dimethylphenylcarbamate) coated or immobilised on silica, separate an estimated 80% to 90% of chiral compounds screened in pharmaceutical laboratories and are the first choice in screening strategies. Coated phases offer excellent selectivity but are restricted in solvent compatibility, while immobilized versions tolerate solvents such as dichloromethane, ethyl acetate and tetrahydrofuran, widening method options. Pirkle-type or brush-type phases, such as Whelk-O, rely on π-π interactions and hydrogen bonding and offer robustness and the ability to invert elution order. Macrocyclic glycopeptide phases based on vancomycin and teicoplanin separate amino acids, peptides and polar compounds in reversed-phase and polar ionic modes. Cyclodextrin phases separate compounds by inclusion complexation and are used in HPLC and widely in gas chromatography. Crown ether phases separate primary amines and amino acids. Protein-based phases using α1-acid glycoprotein, cellobiohydrolase or human serum albumin serve bioanalysis in aqueous conditions. Ligand exchange phases separate amino acids and hydroxy acids using copper complexes. Chiral derivatising agents, such as Marfey's reagent, Mosher's acid chloride and o-phthalaldehyde with chiral thiols, convert enantiomers into diastereomers that can be separated on standard achiral columns, and they are widely used in amino acid and peptide analysis. Chiral mobile phase additives, including cyclodextrins and chiral ion-pair agents, are used less often. Solvents and modifiers, such as hexane, ethanol, isopropanol, methanol, acetonitrile and carbon dioxide with basic or acidic additives, form a significant recurring spend. Column lifetimes of several hundred to a few thousand injections make care and regeneration important cost factors.

Analytical chiral chromatography accounts for the largest number of users and column sales because every chiral drug requires enantiomeric purity testing, while preparative chiral chromatography generates large-volume demand for bulk chiral media in development. Analytical chiral chromatography is used throughout drug discovery, development, manufacturing and quality control to determine enantiomeric excess, verify stereochemical purity and monitor chiral impurities at levels as low as 0.05% to 0.1%. Analytical columns, typically 150 to 250 millimetres long with 3 to 5 micron particles, are purchased in large numbers by pharmaceutical, CRO, CDMO and generic drug laboratories, and pharmacopoeial monographs specify chiral methods for many products. Ultra-high-performance chiral columns with sub-2-micron or core-shell particles shorten analyses to minutes. Preparative chiral chromatography uses larger columns and bulk chiral stationary phase, sometimes hundreds of kilograms in simulated moving bed systems, to isolate grams to tonnes of single enantiomers for toxicology studies, clinical trials and occasionally commercial supply. Simulated moving bed chromatography, a continuous multi-column technique, reduces solvent consumption and increases productivity for large-scale separations and has been used commercially for drugs such as escitalopram. Bioanalysis uses chiral methods to measure enantiomers in plasma for pharmacokinetic studies, often coupled with mass spectrometry. Chiral gas chromatography, using cyclodextrin columns, analyses volatile compounds such as flavours, fragrances, essential oils and some agrochemicals. Capillary electrophoresis with chiral selectors offers an alternative for some analytical applications. Natural product, metabolite and forensic analysis also employ chiral methods, for example to distinguish enantiomers of amphetamines or to authenticate natural flavours. Each application has distinct requirements for column dimensions, particle size and mobile phase, shaping product portfolios. Hyphenated methods combining chiral separation with mass spectrometry are increasingly used to identify enantiomeric impurities at trace levels in complex matrices such as plasma and formulated products.

Supercritical fluid chromatography is the fastest-growing technique for chiral separations because carbon dioxide-based mobile phases cut organic solvent use by 70% to 90%, enable faster separations and simplify product recovery, especially in preparative work. Normal-phase HPLC, using hexane or heptane with alcohol modifiers, was the traditional technique for chiral separations and remains widely used, particularly with coated polysaccharide phases and in established pharmacopoeial methods. Reversed-phase chiral HPLC, using aqueous buffers with acetonitrile or methanol, is preferred for polar compounds, bioanalysis and LC-MS compatibility, and immobilised phases have broadened its use. Polar organic mode, using pure alcohols or acetonitrile with acid and base additives, offers good solubility for many drug compounds and is frequently tried in screening. Supercritical fluid chromatography uses compressed carbon dioxide with 5% to 40% alcohol modifier, delivering lower viscosity and faster diffusion, which allows higher flow rates and shorter run times. In preparative work, carbon dioxide evaporates on depressurisation, leaving purified product in a small volume of modifier, reducing evaporation time and energy. As a result, most large pharmaceutical companies and many CDMOs use SFC as their primary technique for preparative chiral purification, with analytical SFC increasingly used for screening. Gas chromatography with cyclodextrin columns serves volatile chiral compounds. Capillary electrophoresis serves niche analytical needs. Technique choice depends on compound solubility, scale, available instruments, regulatory method history and environmental targets. The growth of SFC has encouraged suppliers to optimise chiral phases and column hardware for high-pressure carbon dioxide conditions, and instrument makers such as Waters, Agilent, Shimadzu and Sepiatec support both analytical and preparative SFC, increasing installed bases that drive column demand. Column hardware rated for higher pressures and solvent recovery systems that recycle carbon dioxide and modifiers are improving the economics of large preparative SFC installations.

Pharmaceutical and biotechnology companies and their CROs and CDMOs account for most chiral chromatography reagent demand because drug regulations require stereo chemical characterization, while agrochemical, flavour, fragrance, academic and forensic users form smaller segments. Pharmaceutical and biotechnology companies are the dominant users, applying chiral chromatography from early discovery, where racemic hits must be resolved to identify the active enantiomer, through development, manufacturing and release testing. Large pharmaceutical companies maintain dedicated chiral separation groups with libraries of dozens of columns and automated screening systems. Contract research and development organisations and CDMOs, including WuXi AppTec, Pharmaron, Lonza, Cambrex, Almac and specialised chiral separation service providers, perform chiral screening and preparative purification for clients and are major buyers of bulk chiral media. Generic drug manufacturers, especially in India and China, use chiral methods to demonstrate enantiomeric purity matching reference products and to meet pharmacopoeial requirements. Agrochemical companies, including Syngenta, Bayer, Corteva and BASF, develop chiral pesticides and herbicides where single enantiomers reduce application rates and environmental load, requiring chiral analysis and sometimes preparative separation. Flavour and fragrance companies such as Givaudan, Firmenich within DSM-Firmenich, IFF and Symrise use chiral GC to authenticate natural ingredients and control stereochemistry that affects aroma. Academic and research institutions use chiral chromatography in asymmetric synthesis research, natural product chemistry and analytical method development. Forensic, anti-doping and clinical toxicology laboratories use chiral methods to distinguish legal and illicit enantiomers and to study drug metabolism. Fine chemical producers use chiral chromatography for intermediates and building blocks. Purchasing emphasises column reproducibility, method transfer support and long-term availability, because validated methods depend on consistent column chemistry. Contract providers often maintain broad column libraries so that clients can obtain screening results quickly, and many offer guaranteed turnaround times for enantiomer isolation of milligram to kilogram quantities.

North America and Europe lead chiral chromatography reagent use because of their concentration of pharmaceutical research and development and regulatory testing, while Asia-Pacific, led by China, India and Japan, is the fastest-growing region with large CRO, CDMO and generic drug industries. North America is a leading region, with the United States home to many pharmaceutical and biotechnology companies, CROs, CDMOs and suppliers such as Phenomenex, Regis Technologies, Agilent, Waters and Thermo Fisher, and with extensive use of preparative SFC in drug discovery. Europe is a major region, with large pharmaceutical research and manufacturing in Switzerland, Germany, the UK, France, Belgium, Ireland and Denmark, strong agrochemical and flavour and fragrance industries, and suppliers including Merck KGaA and Chiral Technologies Europe. Asia-Pacific is the fastest-growing region, as China's CRO and CDMO sector, including WuXi AppTec and Pharmaron, and India's generic and contract manufacturing industries perform large volumes of chiral analysis and purification, Japan is home to Daicel, YMC, Shimadzu and Sumika and a large pharmaceutical industry, and South Korea and Singapore host growing pharmaceutical activity. Chinese chiral column manufacturers are expanding with lower-cost alternatives. Latin America, the Middle East and Africa have smaller markets linked to generic drug manufacturing and academic research.


• 2025 – Waters agrees to combine with BD's Biosciences and Diagnostic Solutions business: Waters, a major supplier of SFC and LC systems used in chiral separations, agreed to a transaction valued at about USD 17.5 billion, expanding its life science tools portfolio.
• 2025 – BIOSECURE Act enacted: The US BIOSECURE Act prompted pharmaceutical companies to review contract research and manufacturing relationships with certain Chinese biotechnology firms, affecting where chiral screening and purification work is performed.
• 2024 – Immobilised polysaccharide phases expand: Suppliers expanded ranges of immobilized polysaccharide chiral phases and smaller-particle columns for UHPLC and SFC, improving speed and solvent flexibility.
• 2023 – EU proposes broad PFAS restriction: The EU's proposed PFAS restriction raised questions about fluorinated additives and materials used in some chromatography applications, encouraging review of alternatives.
• 2022 – Preparative SFC becomes default for pharmaceutical chiral purification: Large pharmaceutical companies and CDMOs reported that most preparative chiral purifications had moved from normal-phase HPLC to SFC to reduce solvent use and cycle times.


Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global Chiral Chromatography Reagents Market with its value and forecast along with its segments
• Various drivers and challenges
• Ongoing trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Polysaccharide-Based Chiral Phases
• Pirkle-Type Phases
• Macrocyclic Glycopeptide Phases
• Cyclodextrin Phases
• Protein-Based Phases
• Crown Ether and Ligand Exchange Phases
• Chiral Derivatising Agents
• Chiral Mobile Phase Additives

By Technique
• Normal-Phase HPLC
• Reversed-Phase HPLC
• Polar Organic Mode
• Supercritical Fluid Chromatography
• Chiral Gas Chromatography
• Capillary Electrophoresis

By Application
• Analytical Separation
• Preparative Purification
• Simulated Moving Bed Chromatography
• Bioanalysis
• Flavour and Fragrance Analysis
• Forensic and Toxicology

By End User
• Pharmaceutical and Biotechnology Companies
• CROs and CDMOs
• Generic Drug Manufacturers
• Agrochemical Companies
• Flavour and Fragrance Companies
• Academic Institutions